<List><item><source>MED</source><extId>28626470</extId><pmcid>PMC5471781</pmcid><annotations><annotation><prefix>clude rivastigmine (</prefix><exact>NCT00130338</exact><postfix>) and cilostazol (NC</postfix><tags><tag><name>NCT00130338</name><uri>http://identifiers.org/clinicaltrials/NCT00130338</uri></tag></tags><id>http://europepmc.org/articles/PMC5471781#europepmc-13b8b0214f93b1743e347e8271e04f13</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>igmine (NCT00130338) and cilostazol (</prefix><exact>NCT00847860</exact><postfix>). </postfix><tags><tag><name>NCT00847860</name><uri>http://identifiers.org/clinicaltrials/NCT00847860</uri></tag></tags><id>http://europepmc.org/articles/PMC5471781#europepmc-8c87ddc0784a7a57000b1c3f561ce17c</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>